price month
hold dividend wait growth
initi coverag gilead neutral rate tp gilead
remain transit period sens recent appoint new
ceo financi perspect believ earn
trough acceler back growth like gilead dividend
current yield approach capit alloc still emphas
need fill later-stag pipelin
multipl rel peer vs median larg cap biotech
major pharma could see expans
light absent detail
comfort current rel valuat neutral rate gilead
share like base-busi need detail around
long-term growth trajectori busi improv
hiv busi revenu main revenu driver led
flagship asset biktarvi bullish hiv franchis believ
drive revenu next year proprietari physician survey
posit biktarvi favor nave switch patient
cautious optimist new ceo strategi gilead call
got hint ceo daniel oday strategi gilead like focu
strengthen pipelin ensur commerci excel need
see execut fulli comfort plan compani
valuat risk valu share use sum-of-the- part dcf
wacc tvgr analysi support tp
risk includ commerci relianc hiv drive revenu ip gilead
patent challeng revenu could risk clinical/development
clinic trial failur could impact share regulatori fda ema could
reject delay approv filgotinib descovi prep market/
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
inc biopharmaceut compani
engag research develop commerci
medicin area infecti diseas oncolog immunolog
area unmet medic need
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
sky scenario model probabl success
yescarta expans well filgotinib also assum
success mid-stag nash asset exclud selonsertib
maintain base case third line yescarta hiv hcv sale
grey sky scenario model car-t platform
success beyond dlbcl filgotinib program delay
fail meet base-cas expect nash program fail
maintain base case third line yescarta hiv hcv sale
 close
tabl content
guidanc consensu expect
hiv domin pois continu biktarvi consid gold standard among
doc competit threat limit
filgotinib potenti strong competitor crowd space
cell-therapi franchis unlik drive signific top-lin growth near term
like new ceo strateg prioriti await
nash back draw board follow failur
hcv main driver revenu earn upsid busi
holt view gilead
cs peer relationship gilead
nash primer
fda guidanc nash
new day gilead evolut back earn growth gilead larg cap
biotechnolog compani focus develop commerci small molecul
drug treat infecti diseas hiv hcv beyond infecti diseas compani
also cell therapi platform acquisit kite develop novel cancer
treatment gilead cross-road evolut compani gone day
annual hepatitis-c franchis hcv sale new growth predic
pipelin execut acquisit see begin revenu earn
growth need clariti execut compani evolut follow
earn call start get sens new ceo daniel oday
strateg vision gilead emphasi pipelin expans commerci
excel still share near five-year low think investor need see
action becom comfort upsid case compani absent
clear growth lever share could becom valu trap upsid
driven dividend share repurchas neg gilead without
quantifi driver share out-performance rate share neutral thesi could
chang accret clariti launch filgotinib earli without need
manta trial chang current hiv market dynam favor gilead pleas
see industri report detail larg cap biotech sector
neutral rate gilead share three main reason like base hiv
busi see outsiz growth would significantli alter earn
project cell-therapi import platform sale yescarta
like never gener revenu akin sovaldi/harvoni unlik biogen
under-perform think multipl somewhat protect contract
new strateg vision acquisit could see expans
one-year price base base-cas dcf analysi
assum wacc termin growth rate fulli dilut share
outstand wacc premium bloomberg wacc gilead
industry-lead hiv hcv franchis matur busi serv larg patient
popul gilead product best-in-class standard-of-car howev
declin patient start hcv gener competit hiv expect reduc
overal signific forecast period hiv hcv sale compris
project revenu declin futur cash flow
increasingli depend gilead late-stag pipelin oncolog inflammatori
diseas view highli competit market expect gilead
commerci regulatori research expertis benefit program new
market compani requir new strategi new ceo incorpor
elev execut risk valuat assumpt via wacc
risk upsid risk commerci risk better-than-expect sale market soon-
clinical/development risk better-than-expect clinic result mid- late-stag
asset busi develop risk current assum major
model valuat gilead engag transform could see near-term
downsid risk commerci risk poorer-than-expect sale market soon-to-b
market asset ip risk patent challeng expir earlier expect
gener manufactur abl launch sooner clinical/development risk
gilead late-stag asset fail clinic trial regulatori risk fda ema delay
reject market applic approv gilead pipelin asset
external/market risk macroeconomic issu govern polici broader
market issu neg impact gilead share
asset allow
multipl unlik contract rel peer pay
growth gilead share trade warrant forward price-to-earnings discount larg cap
biotech peer vs pharma view larg
cap biotech trade gilead given believ larger structur
issu downsid risk warrant cash flow valuat perspect
think hiv hcv fairli valuedeven dominant-shar hiv
like continu per physician check proprietari survey yescarta cell
therapi franchis repres interest innov howev continu believ
commerci remain challeng vi -- vi autolog competitor emerg
novel bispecif potenti allogen option past
readout fairli confid filgotinib leader immunolog
space follow posit data trial see limit
downsid risk current trade level howev clariti stori evolv back
growth expect signific multipl expans near term
dividend yield reason hold share near-term gilead
larg cap biotech compani reliabl pay dividend current dividend yield
respect current pay dividend share
repurchas primari vehicl capit return sharehold gilead dividend
compar favor major pharma peer compani pay
higher dividend major pharma mean think gilead dividend
yield make rel attract vs regeneron oday outlin
intent keep attract dividend polici view posit even
current dividend yield think gilead engag
proprietari hiv survey suggest continu domin prefer gilead
srt despit potenti gener threat recent launch viiv dovato
survey physician believ efficaci combin safeti benefit taf-
base regimen continu domin treatment landscap viiv doublet
dovato dolutegravir lamivudin compar efficaci safeti clinic trial
set physician tend prefer three-drug biktarvi due perceiv
benefit lower resist risk generic hiv market like
impact brand sale survey physician continu favor simpler
regimen better safety/clin profil valuat perspect hiv
busi account nearli dcf sale asset compris
major revenu base compani detail survey result later
report
cell-therapi franchis growth profil project compound-annual-growth-rate
still estim sale yescarta enough re-rat
share investor pressur deal result acquisit kite august
believ expens side may gener immedi
return sharehold unlik acquisit pharmasset even
acquisit triangl expans import area futur treatment
cancer posit view still see headwind competit pressur
longer -term current iter manufactur administ yescarta
challeng like prevent rapid uptak use gilead
asset kite platform develop concern recent
discontinu bcma program view multipl myeloma valuabl
market note mani asset earli stage develop
also think emerg novel bispecif allogen car-t could blunt
sale current gener product
new ceo daniel oday roch pharmaceut experi run
success commerci organ howev gilead roch backbon
differ mr oday knowledg oncolog rare diseas time
roch limit histori deal make believ gilead need quick
win translat commerci success howev roch tradit taken
longer relax approach trial doubt effect leader
need see translat strategi execut consist commentari
expect evolut revolutionsuggest take time get
know organ prior make major structur chang
strong strateg prioriti yet wait execut first glimps oday
earn call got sens understand urgenc fill
later-stag pipelin submit market applic filgotinib soon possibl
focu commerci deliveri think right strateg approach gilead
especi pipelin contrast manag appear less
awar pipelin gap also think priorit filgotinib work fda file
ahead manta data underscor import asset compani
recal fda want data male testicular safeti studi patient ulcer
coliti despit posit safeti data robust phase rheumatoid arthriti program
commerci front think effort acceler sale yescarta would
seen posit think formal separ kite distinct busi unit could
help foster innov akin roch handl genentech
recent deal announc oday yet enough move needl
recent announc partnership novo nordisk nash combin therapi
develop goldfinch kidney diseas therapi reflect oday
deal make roch latter partnership small invest gilead
up-front cash includ equiti invest give compani access
earlier-stag asset kidney diseas gilead receiv exclus option licens right
product deriv goldfinch kidney genom atla reflect big data
approach drug develop still hope larger later-stag deal could
filgotinib could revenu growth gilead follow recent posit
data trial potenti best-in-class potenti
upsid file possibl without manta good clinic profil
believ support regulatori approv think filgotinib one gilead
star pipelin asset still increasingli crowd space ra ibd think
launch would strong significantli alter current revenu base
gilead key debat remain around necess manta trial data set file
someth gilead current engag fda address data set requir
could see launch back-half requir could push
least one year later success filgotinib mostli price view
data three pivot trial ra yet think gener view manta
requir file updat suggest manta requir could drive share
upsid estim end-us sale reach slightli consensu
would character gilead good enough given earn beat
slight revenu miss biktarvi far exceed street expect beat
consensu stronger expect launch europ importantli
call first earn call new ceo like tone strateg
prioritiesespeci commentari priorit busi develop whole
need see execut becom posit share follow
expand pipelin abl acceler approv filgotinib could
posit stock
near-term outlook given strong hiv busi potenti best-in-class asset
filgotinib set weaker pipelin grow cell therapi franchis believ
gilead share perform in-lin rel peer coverag univers
highlight gilead need grow revenu base late-stag pipelin
rel think need less urgent could see share upsid
hiv includ continu commerci progress biktarvi clariti file plan
filgotinib even increment updat cell therapi franchis think
anoth nash disappoint atla worse-than-expect hcv sale abil
new ceo execut state goal could drive share downsid given current
put take gilead see signific reason multipl expans
see reason contract balanc
expect share trade rang bound absent signific strateg shift immedi
long-term outlook long-term think much gilead success failur
rest drive next leg revenu earn growth view
project trough year earn nearli ep tepid growth
expect next year hope new ceo clearli articul
execut strategi chang trajectori busi time hiv
project slow even biktarvi yescarta peak around
ww revenuespoint need growth beyond current busi
line absent clear strategi like includ sort transact
transact could see multipl compress long-term
credit suiss rel view peer rel peer gilead trade discount
price-to-earnings basi except forecast current base-busi rel flat
long-term growth biktarvi off-set patent expir competit hiv
continu contract hcv busi pipelin perspect think
gilead remain leader infecti diseas lag nash oncolog
project modest growth rel peer univers think gilead could
continu view buyer weak bad
strength vertex assess place gilead middle-to-back
pack problemat less excit upsid opportun
guidanc consensu expect
slightli ahead revenu consensu expect non-gaap ep
neutral thesi base flat top-lin revenu matur hiv hcv busi
near middl guidanc consist neutral rate figur slightli
ahead factset consensu similarli product gross margin middl guidanc
estim lower sg expens compar guidanc
neg data gilead nash drug selonsertib gilead updat
guidanc earn despit failur selonsertib significantli
consensu expect expens street number may updat
reflect chang tax rate line consensu guidanc estim
differ dilut non-gaap ep compar consensu
provid
capac transact near-term need gilead signific capac
acquir healthi cash balanc see figur analysi gilead
deal capac expect gilead take addit debt
compani cash balanc futur cash flow enough complet deal
even continu share repurchas estim capac
gilead better posit vs gilead need replac
revenu less immin due best-in-class hiv franchis view gilead base
busi face less near-term headwind howev hiv franchis
face gener competit next sever year threat coupl
declin hcv franchis recent failur nash lower-than-expect yescarta
sale signifi gilead would need acquir mid-to-l stage asset bolster
pipelin revenu de-risk depend hiv sale posit
filgotinib would like see near-term asset higher potenti henc see
gilead buyer weak contrast alreadi launch
divers biosimilar busi pipelin asset replac compani matur
figur deal capac
expans cell therapi
yescarta sale abl grow credit suiss
consensu expect driven increas quicker manufactur
increas patient demand better-than-expect administr
center capac gilead success abl expand pi
yescarta earlier line therapi dlbcl tumor
therapi kite allogenic-bas platform
overal car-t remain prefer treatment heme-onc
yescarta sale continu lag below-consensu cs
result near-term gilead unabl shorten manufactur
time coupl decreas demand growth less-than-
expect center capac gilead unabl expand current pi
yescarta gain traction earlier line therapi
success develop cell
therapi forc write kite acquisit
autolog car-t therapi remain nich novel bispecif
allogen car-t platform take greater share heme-onc
unabl
think yescarta sale continu modest make difficult justifi price paid kite still long run
think cell therapi novel oncolog modal kite platform could import gilead competit
think yescarta remain favor option speak physician launch bristol/celgen unlik hamper
sale enough capac three asset co-exist neg see signific expans earlier
line therapi novel bispecif allogen car-t therapi like use set could also competit
threat advanc patient beyond yescarta see limit success earlier-stag product base recent write
ii durabl hiv busi
gilead continu remain domin player hiv
busi continu strong uptak taf-bas regimen
name biktarvi us row gener unabl
dent sale durabl growth given physician prefer
simpl singl tablet safe efficaci regimen viiv
doublet regimen enjoy limit uptak physician continu
prefer three-drug regimen protect viral resist
develop advanc
success
gilead market share heavili impact brand competit
gener entrant taf-bas regimen still remain
import therapi greater-than-expect uptak viiv
doublet regimen gener competit us
ou take greater-than-expect share payer push patient
less expens option effort produc littl failur
novel anti-hiv therapi function cure
base physician check proprietari survey believ gilead remain domin player hiv led
continu success biktarvi taf-bas regimen gener like limit impact us physician prefer
patient treat latest efficaci safe therapi ou generic market like line
expect note mani european govern may opt less expens option believ viiv doublet unabl gain
signific share despit posit data physician prefer three-drug regimen prevent viral resist limit data
develop asset hiv think gilead remain leader virolog understand diseas increas likelihood
success one asset
daniel oday abl success navig gilead top
bottom-lin earn growth intern restructur acceler
cell-therapi franchis extern oday leadership
abl help reacceler growth end
abl success merg big pharma cultur
biotech cultur gilead
daniel oday big-pharma style leadership clash
gilead biotech mental deliv reacceler
revenu earn act quickli enough
restructur compani improv intern engin
cell therapi franchis continu struggl despit
experi roch oncolog signific extern
 help drive growth
given oday track record roch believ effect leader gilead think take time
learn organ understand need chang get sens appreci urgenc bolster later-
stage pipelin support current commerci busi less quarter tenur need see oday execut
strategi recent outlin
ceo
data
finch
fda
step
fail
yescarta approv canada
r/r larg bcl chemo
charl martineau univers toronto figur forward price-to-earnings comparison gilead vs
figur forward price-to-earnings comparison gilead vs larg cap biotech
charl martineau univers toronto figur forward price-to-earnings comparison gilead vs pharma
figur current dividend yield rel peer
compani
charl martineau univers toronto figur gilead pipelin asset catalyst
complet phase studi hiv cure
data phase studi
data phase studi
complet enrol phase studi
data atla phase
data phase studi
submiss eu
updat fda file
complet enrol divers phase
data select phase
data phase
data phase
initi phase studi uc
data registr studi
data phase combin studi
complet enrol pivot phase
preliminari data phase studi
may/jun phase data present
complet enrol phase studi
data registr phase studi
may/jun phase data present
complet enrol pivot phase
data phase phase pivot studi
may/jun phase data present
complet enrol phase studi
initi clinic studi allogen car-t
complet enrol phase
one-year price target deriv base-cas dcf analysi
assum wacc termin growth rate fulli dilut share
outstand wacc premium bloomberg wacc gilead
industry-lead hiv hcv franchis matur busi serv larg patient
popul gilead product best-in-class standard-of-car howev
declin patient start hcv gener competit hiv expect reduc
overal signific forecast period futur cash flow increasingli
depend gilead late-stag pipelin oncolog inflammatori diseas
view highli competit market expect gilead commerci
regulatori research expertis benefit program new market
compani requir new strategi new ceo incorpor elev
execut risk valuat assumpt via wacc
forecast cash flow account known expect product launch
patent expir competit threat current portfolio pipelin beyond
forecast period appli termin growth rate cash flow expect
gilead continu invest busi develop effort success
replac portion revenu lost eros yet convict
probabl success po estim across coverag univers gener
appli follow po estim asset variou stage develop enter
phase enter phase enter phase asset
nda/bla stage rare diseas patient assign standard
probabl phase phase phase bla/nda
assumpt fda work close manufactur design
implement clinic program also adjust po estim base clinic data
phase compel phase neg yet compani move
pivot trial gilead assum indic current near bla file
support po rheumatoid arthriti ra indic indic
ulcer coliti crohn diseas phase trial support po
slightli higher base po indic seen posit
safeti data ra trial
sensit analysi suggest valuat rang across variou termin
growth discount rate one-year price target repres premium
gilead recent close price figur figur
figur gilead dcf analysi base case
royalti contract revenu
increas /decreas wc
royalti contract revenu
dilut share current price
dcf sensit analys includ sensit analys help support
valuat look differ wacc tvgr figur assum lower growth
tv still see dcf valuat higher current share price
figur dcf sensit wacc tvgr varianc
scenario share sky scenario model probabl
success yescarta expans filgotinib also assum clinic success
mid-stag nash asset exclud selonsertib includ model case
gilead maintain base case third line yescarta hiv hcv sale
grey scenario share grey sky scenario model car-t
platform success beyond dlbcl also assum delay filgotinib
approv launch hamper peak sale mid-stag nash program fail
maintain base case third line yescarta hiv hcv sale
commerci risk better-than-expect hiv/hcv cell-therapi product
sale current assum declin hcv slow cell-therapi sale gilead
abl better commerci asset sell predict
revenu earn like higher forecast could
posit impact share price
extens lack gener competitor could posit impact sale small-
molecul product compris major compani revenu base
clinic develop risk better-than-expect clinic result late-
stage asset current low expect compani nash
develop program cell-therapi program beyond yescarta compani
abl success develop nash asset cell-therapi asset could see
share upsid current estim
busi develop risk current assum compani
transform busi develop compani engag
accret acquir late-stag asset entir compani could see
reacceler revenu earn growth
commerci risk sale key asset hcv hiv cell-therapi
franchis base dcf valuat sale wors
consensu expect could see gilead share pressur see potenti
revenu concentr risk hiv busi compani longer
abl gener revenu franchis due competit patent loss
factor could see significantli neg impact share
ip risk much gilead commerci busi base small molecul asset
limit patent life gener manufactur success challeng
gilead key patent signific portion compani revenue-bas
may risk loss major patent either us ou could
clinic develop risk valuat share upsid
potenti base outcom clinic trial gilead late-stag
asset shown clinic ineffect unsaf would expect neg
pressur gilead share
regulatori risk fda ema approv requir gilead market
sell therapeut delay outright reject approv
investig asset could neg impact futur cash-flow
valu gilead share fda ema could revok market
author market product due safeti efficaci concern
demonstr post-market set
external/market risk biotechnolog remain volatil sector
affect extern factor includ drug price legisl intellectu properti
law healthcar polici overal economi neg polici develop
and/or weaken economi could impact gilead share price
continu biktarvi
gold standard among doc
competit threat limit
gilead industry-lead taf-bas portfolio continu provid
solid defens revenu foundat gilead core busi compris
medic treat prevent hiv sale asset compris major
revenu base compani gilead hiv franchis remain protect multipl
patent
compris multipl drug concern revenu
concentr riskespeci patent key compon taf challeng
see figur view speak expert infecti diseas gilead
like remain leader hiveven recent launch dovato novel doublet
therapi viiv potenti gener impact europ forecast
impact us earli franchis product taf
tenofovir alafenamid fumar emtricitabin backbon taf newer version
older drug use main compon gilead single-t regimen
safer afford longer exclus gilead franchis
recent launch biktarvi seen mani treat physician gold
standard treatment infect multi-drug str optim side-
effect profil better gilead combin therapi excel efficaci still
despit gold-standard hiv treatment slightli consensu
expect could greater impact gener franchis long-term
see figur assum flat compound-annual-growth-rate vs consensu also think
hiv franchis like shrink truvada face gener competit us
long-term view franchis limit growth core neutral thesi
gilead share neg believ hiv alon significantli alter
growth profil compani
figur hiv compon gilead revenu base
biktarvi lead franchis long term best-in-class treatment hiv
believ biktarvi combin safeti efficaci toler three-drug single-
tablet regimen str set clearli apart expect physician prefer continu
favor near term view competit threat viiv dovato
inject cabotegravir limit neither address treatment select prioriti
comprehens biktarvi anticip degre eros gener str
launch greater extent consensu us check doctor
suggest cost consider current primari driver treatment select
efficaci safeti conveni import factor forecast compound-annual-growth-rate
us intern anticip european govern may favor lower-
price therapi even patient requir take multipl tablet forecast eu
compound-annual-growth-rate row compound-annual-growth-rate help frame view hiv franchiseespeci
launch biktarvi dovatow conduct hiv-focus physician
survey overal three key takeaway survey physician priorit
efficaci safeti conveni treatment select strong prefer
develop biktarvi treatment-experienc treatment-nav popul
prefer gilead product like persist face near-term
competit new product gener detail assess next
survey data suggest gilead continu market leadership within hiv
treatment assess current state hiv market us conduct
survey intern medicin physician specialti infecti diseas
select physician current practic us varieti treatment
practic non-academ hospit respond report see
hiv patient per month averag mean total patient
treatment-nav patient treatment-experienc patient patient cover
survey physician indic privat insur cover
medicaid cover medicar
efficaci dose conveni safeti receiv equal consider
treatment select among secondari factor drug-to-drug interact number
drug regimen receiv high prioriti figur respond indic strong
prefer taf-bas regimen single-tablet regimen
conveni figur believ biktarvi combin safeti efficaci
taf-bas three-drug str make competit offer major case
enhanc toler drive increment switch treatment-experienc
figur averag report prioriti factor influenc treatment
drug
patient
figur degre agreement statement aspect hiv
biktarvi carri hepersensit reaction
associ abacavir
biktarvi singl tablet conveni
lack sleep disturb associ
biktarvi better efficaci doluegravir-bas
concern taf regimen could
impact bone kidney health tdf regimen
would prescrib biktarvi dolutegravir-bas
disagre strongli neither disagre agre agre strongli
clear prefer biktarvi emerg usag anticip increas
near term respond indic prefer biktarvi treatment-
nave treatment-experienc set figur figur physician report
usag biktarvi treatment-nav case treatment-experienc
charl martineau univers toronto set respond anticip increas usag biktarvi follow
month market share captur primarili tivicay triumeq figur
figur weight score hiv therapi
treatment-nav set forc rank
frequenc use
figur weight score hiv therapi
rank frequenc use
figur anticip usag
time treatment-nav set
figur anticip usag
enthusiasm two-drug includ viiv dovato dolutegravir
lamivudin modest respond felt current avail clinic data
therapi moder significantli compel figur two-year
safeti data may drive increment willing prescrib survey physician indic
increas potenti diseas resist two-drug regimen outweigh
potenti benefit reduc toxic figur check support notion among
prescrib patient higher number drug regimen favor due better
perceiv abil mitig develop diseas resist figur data
trial pivot data dovato vs biktarvi pivot trial
view gilead main competitor hiv space viiv healthcar jv gsk
survey speak physician suggest gilead product
like remain market leader next year janssen js pharma
divis also competit product use taf-bas backbon gilead get
royalti payment merck could competitor long-act space yet
see concret clinic data suggest compani near-term threat
figur respond assess avail
clinic data percentag total
figur degre agreement statement
two year safeti data
use
barrier diseas
resist
regimen outweigh
potenti benefit
neither disagre agre
virolog data week window
discont studi drug due ae
discont due reason
miss data window studi
physician believ long-act inject disrupt potenti near
term safeti dose profil must superior current daili
absent long-act inject administ home minim pain
subcutan think remain primari method treatment
hiv-infect individu physician survey excit prospect
therapi note current profil long-act inject less desir
end note viiv inject cabotegravir rilpivirin develop requir
once-monthli intramuscular rather subcutan administr qualifi
profession beyond potenti disrupt long-act inject anticip
gener may erod brand sale longer term note reimburs cost
consider current littl impact us treatment select figur
figur anticip caus disrupt hiv market
year percentag respond
oral therapi
intermitt
prep like see continu growth respond anticip increas usag
truvada prep follow year believ still signific room
penetr truvada prep vs estim address per cdc
anticip approv physician prefer taf-bas regimen
regular treatment set carri descovi prep given demonstr non-
inferior enhanc safeti profil via reduc impact bone kidney health
rel truvada account prep forecast compound-annual-growth-rate
cdc may patent gilead truvada prep highlight potenti
risk truvada prep recent headlin us depart justic
investig whether cdc assert patent right use truvada
hiv prevent note report indic cdc right
composit matter truvada emtricitabin tdf rather dose method
use patent weaker still given current polit environ link
letter senat stabenow regard patent issu could see pressur
legisl forc some-sort royalti payment settlement recent gilead
agre give away free drug year patient includ
truvada like to-be-approv descovi prep minim impact
forecast prep usag patient receiv free drug account
model gilead also allow gener truvada market septemb
earlier previous disclos note descovi prep like
approv prior could help gilead maintain share believ descovi
prep safer altern truvada
descovi prep like approv octob truvada use old tdf
backbon drug combin emtricitabin prevent hiv infect gilead
shown figur newer version truvada brand name descovi work
truvada better safeti profil descovi use newer taf medicin
backbon combin emtricitabin unclear cdc hold patent use
descovi prep note descovi enjoy patent exclus least
potenti year hatch-waxman extens descovi could help insul prep
busi gener us safeti profil drug superior truvada
figur phase discov descovi vs truvada prevent hiv
treatment
number patient
p-valu non-inferior
mean chang spine bmd week
mean chang hip bmd week
mean creatinin clearanc week
gilead hiv franchis like remain key contributor revenu cash flow
view biktarvi like help sustain durabl gilead hiv franchis
long-termg superior safeti efficaci profil vs gilead
competitor believ drug comprehens address treatment
prioriti identifi survey major case believ
prefer gilead product physician persist near term
expect impact competit launch minim name viiv
juluca dolutegravir lamivudin domest anticip introduct
gener mitig priorit outcom cost taf-bas
regimen superior safeti profil especi patient chronic art
intern anticip european govern favor lower-cost therapi
extent greater consensu expect visibl earlier-
stage hiv asset limit believ gilead demonstr strong abil bring
innov product market space figur hiv market
model figur overview patent expir across gilead hiv portfolio
includ potenti patent extens
atripla gener
biktarvi gener
complera eviplera gener
descovi gener
genvoya gener
odefsey gener
stribild gener
truvada gener
viread gener
compani data credit suiss estim exclud symtuza hiv emtriva tybost
atripla gener
biktarvi gener
complera eviplera gener
descovi gener
genvoya gener
odefsey gener
stribild gener
truvada gener
viread gener
compani data credit suiss estim exclud symtuza hiv emtriva tybost
next-gener hiv asset beyond current portfolio gilead also develop
novel potenti longer-act drug treat prevent hiv earli
develop highlight vesatolimod agonist potenti
function cure hiv infect function cure patient control viru
one immun system make patient undetect unabl transmit
differ steril cure trace viru remov bodi
includ integr viral genet materi immun system cell type cure
farther away would requir use genom edit gene therapi could get
data phase studi vesatolimod year-end earli
expect data capsid inhibitor nrti
capsid inhibitor could backbon long-act anti-retrovir treatment hiv
see link phase clinicaltri gov entri could transform hiv
treatment daili oral pill once-monthli even less frequent inject note
physician excit potenti longer-act option type drug
could also use hiv prevent novel revers transcriptas inhibitor
enzym use hiv form dna viral rna asset could use
patient resist older art drug clinicaltri gov entri
phase trial overal think current franchis rel durabl
especi light competit gener innov
manufactur like earlier work next-gener hiv treatment
believ data earli make call also highlight gilead
major hiv market us europ figur suggest
innov would take share other rather help maintain
truvada agent
filgotinib could area revenu upsid away hiv hcv gilead
recent posit data ra despit good clinic profil
support regulatori approv filgotinib vacuum enough move
needl gilead view inde much upsid larger ra indic
price stock estim peak unadjust ww sale ra see
figur follow failur selonsertib patient advanc mid-stag
fibrosi nonalcohol steatohepat nash trial
filgotinib remain nearest-term investig asset highest impact potenti
like large-scal develop plan could take advantag jak efficaci
across inflammatori diseas see figur jak space crowd filgotinib
could fourth market behind pfizer xeljanz lilly/incyt olumi
upadacitinib think asset clinic profil could differenti enough
command market share overal data indic safeti look better competitor
name lilly/ incyt olumi pi link caution need see complet data
across ra trial make full claim regard safeti filgotinib detail
compar view safeti efficaci across class later section
gener posit asset ra investig indic
concern filgotinib gener enough near-term revenu
acceler top- bottom-lin growth gilead
clariti need file timelin manta safeti studi could gate
factor data phase finch trial posit
note gilead partner galapago yet articul strategi path
file key unknown whether fda requir result phase
manta male testicular safeti trial prior submiss fda requir data
could see file launch would delay
fda requir data manta trial gilead yet disclos
trail complet highlight recent commentari compani
suggest full data set compani may abl file
approv ra ahead manta believ updat could better posit
addit upsid possibl ibd indic ulcer coliti crohn
data trial posit data expect
select divers expect addit upsid given
potenti addit peak sale ulcer coliti crohn diseas
collect ibd beyond ra ibd expect data smaller opportun includ
lupu sjgren syndrom
phase trial rheumatoid arthriti imflammatori bowel diseas
long-term extens adult ra
biolog experienc nave
long-term extens adult uc
biolog experienc
long-term extens adult cd
enrol invit
activ recruit
enrol invit
enrol invit
adult
adult sbcd
adult sj
adult cle
adult lme
adult uveiti
activ recruit
activ recruit
activ recruit
actual estim primari complet
file approv ra
filgotinib later market potenti best-in-class oral jak rheumatoid
arthriti encourag emerg clinic profil filgotinib see
possess best-in-class potenti amongst lead oral jak inhibitor data
finch program suggest excel efficaci varieti patient type
compar jak includ abbvi upadacitinib pfizer xeljanz
lilly/ incyt olumi provid complet cross-trial comparison filgotinib
asset appendix
filgotinib efficaci also appear better market leader humira view
posit signal on-going head-to-head finch trial humira stabl
dose methotrex see figur filgotinib show clear dose respons
higher acr rate mg dose mg placebo-adjust basi
respons rate dose
dose week respect placebo-adjust rate
mg placebo-adjust
rate finch trial also demonstr
statist signific efficaci patient adequ respons diseas
modifi anti-rheumat drug dmard see figur nave
charl martineau univers toronto figur efficaci intoler vs humira
perhap importantli safeti profil filgotinib look quit clean seriou
advers event rate discontinu rate due treatment-emerg advers event
similar across group importantli report case deep vein thrombosi
dvt pulmonari embol pe although one case non-seri retin
vein occlus dose see figur
key outstand issu filgotinib relat concern around potenti male testicular
toxic given advers event seen preclin rat dog toxicolog studi
fda determin suffici safeti margin filgotinib exposur
no-observed-adverse-effect-level noael observ studi
anticip human exposur mg daili filgotinib dose result male
subject darwin us dose select
divers trial evalu filgotinib male subject us may
receiv fail prior therapi includ anti-tnf entyvio
similar concern seen human trial regul outsid us appear
comfort issu fda requir compani conduct manta
safeti trial better assess situat unfortun enrol trial prove
challeng fda insist trial complet prior submiss
could delay us regulatori file later current estim
file approv us
delay launch product would especi worrisom given
competit rheumatoid arthriti market product enter
xeljanz market number year lilly/incyt olumi
approv earlier year although lower dose upadacitinib
also expect enter market late mean filgotinib fourth oral jak
enter rheumatoid arthriti market howev filgotinib efficaci safeti
hold variou on-going clinic trial market opportun much larger
competitor given wide rang indic may get util
charl martineau univers toronto figur safeti profil appear favor filgotinib vs jak inhibitor
due ae
ibd shape becom major area develop filgotinib portfolio
pivot phase trial on-going treatment crohn diseas
ulcer coliti filgotinib phase fitzroy studi previous
shown promis efficaci safeti profil cd compar favor current
market therapi includ cd heavyweight newer entrant like stelara
entyvio figur almost patient activ arm respond treatment vs
placebo place filgotinib potenti best-in-class therapi cd assum
phase upcom phase trial data translat real world outcom
charl martineau univers toronto figur phase fitzroy data encourag filgotinib cd induct
therapi anti-tnf naiv patient
filgotinib select trial uc includ interim futil analysi serv
phase part integr phase program independ data
monitor committe dmc conduct plan interim futil analysi
patient complet induct period phase portion studi dmc
recommend studi proceed phase plan mg
mg daili dose level biologic-experienc biologic-nav patient
cd uc market repres combin ww sale annual
current domin anti-tnf biolog notabl humira remicad
present xeljanz jak inhibitor approv ibd specif treatment
moder sever activ uc use come addit risk
patient develop anemia decreas erythropoietin product think
filgotinib could avoid given higher select jak vs jak fact laboratori
data filgotinib studi demonstr increas hemoglobin filgotinib
much like ra stori see yet anoth larg potenti highli lucr market
opportun filgotinib assum success develop launch next
year given favor efficaci safeti demonstr thu far well
conveni once-a-day oral pill vs needle-bas inject
creat new opportun beyond ra ibd current earli stage
develop gilead galapago aggress pursu autoimmun
disord believ could becom highli accret filgotinib franchis
next three five year current compani activ phase trial ankylos
spondyl uveiti sjgren syndrom lupu relat condit well
three-year long-term extens studi psoriat arthriti follow success
complet phase equat trial figur collect phase market
project grow compound-annual-growth-rate becom ww opportun
help acceler galapago growth valu creation assum commerci
launch one market
figur multipl phase trial underway assess new target beyond ra ibd
indic number
efficaci safeti filgotinib adult
studi filgotinib activ
safeti efficaci filgotinib
femal w/ mo dto sev activ
safeti efficaci studi filgotinib gs-
tirabrutinib adult w/ activ
safeti efficaci filgotinib
adult lupu membran nephropathi
initi phase filgotinib data psoriat arthriti ankylos spondyl
publish highli encourag success indic
figur figur respect repres attract market opportun
global accord consensu estim forecast consensu
reach notwithstand competit market price condit
view smaller nonetheless sizabl market opportun us
global filgotinib oral jak inhibitor could play meaning role
charl martineau univers toronto figur filgotinib shown reduc dapsa baselin vs placebo
figur filgotinib shown reduc asda baselin vs placebo
gilead lead commerci filgotinib us galapago
commerci product select countri eu estim
peak adjust end-us sale go
cell-therapi franchis unlik drive signific
cell therapi franchis nice-to-hav platform unlik move
needl think gilead foray cell therapi via kite
acquisit could set compani longer term major player cell therapi
space concern growth like remain anem inde sale
yescarta guid grow
repres growth y/i like take year reach sale
estim use believ aggress assumpt share
health system capac project peak sale
believ competit novarti bristol/celgen other could hamper growth see
figur estim vs consensu figur view evolut
dlbcl market given estim think purchas price kite
ok best certainli immedi accret like gilead acquisit
pharmasset said longer term think move novel heme-onc
therapeut smart strateg move gilead near-term revenu upsid
enough re-rat share speak compani much kite
acquisit cell therapi platform vs specif product agre
long-term platform import need see clinic data fulli justifi
acquisit write anti-bcma asset boost
manufactur health system capac remain key concern
commerci success car-t therapi number author center
significantli januari us europ prior ww
challeng remain entir commerci infrastructur requir manufactur
administ product note vein-to-vein time remain approxim day
patient cell extract modifi car-t cell
infus speak gilead improv like remov day
novarti current similar vein-to-vein time line believ
could reduc time around day improv manufactur think
reduct day would meaning competit advantag novarti
could hamper use yescarta given current limit think anyth
day declin manufactur process possibl
know effici bristol/celgen manufactur aka
lisocabtagen maraleucel liso-cel assum vein-to-vein time line
gilead novarti current experi
beyond manufactur administr reimburs challeng health
system privat insur us reimburs car-t therapi
associ administr cost read report reimburs delay see
swetlitz hospit save live car-t get paid anoth stori stat
news march hospit administ car-t therapi must take signific
financi risk administ yescarta kymriah still note earli inning
believ space constrain rather financi risk limit use car-t
therapi wac yescarta plu cost administ drug
easili note stem-cel transplant good proxi cost
administ car-t therapi accord american cancer societi cost
medicar lack full reimburs car-t current pay
drug cost plu cost administ highlight yet final
payment model car-t therapi seem limit use older adult
inde administr seema verma admit medicar payment
system car-t therapi work hospit stand lose money
patient treat dlbcl diseas older adult common patient year
mani may qualiti medicar regardless lack robust payment
structur car-t medicar sever limit uptak popul may
benefit payment outpati administr medicar could lucr
hospit encourag use center perform treatment
set speak gilead approxim elig yescarta patient would
cover medicar regardless verma understand payment yescarta
need updat
like continu engag reimburs car-t therapi
medicar patient current rule fulli reimburs car-t therapi leav
hospit respons nearli patient believ work
manufactur provid come reason reimburs scheme
cover cost open access expect addit updat
gilead progressnot good portion elig popul mani
therapi medicar age
overal think combin long expens manufactur time
complex expens administr make car-t commerci difficult
slow uptak question current infrastructur abl support move
earlier line therapi note gilead examin use yescarta second line
high-risk front line patient believ allogen car-t therapi potenti
novel bi-specif could major role dlbcl market ultim approv
european reimburs remain slow although surprisingli nh england
approv use us ou launch remain slow country-by-countri
negoti must occur reimburs current yescarta avail uk
recent approv fund cancer drug fund see link franc atu
program germani believ ou reimburs remain slow
estim ou sale uk yescarta list
price confidenti discount taken actual
reimburs rate franc temporari reimburs approxim per
patient howev note final price negoti gilead respons
rebat back differ cost franc germani earli access current law
allow one year free price final reimburs price negoti
estim yescarta price similarli kymriah approxim per
patient longer term estim approxim discount base discuss
european colleagu eu price us list price calcul averag
row price approxim per patient
car-t remain competit field three main player dlbcl space
target asid novarti gilead also compet
bristol/celgen assum approv per cvr
structur bristol/celgen deal across therapi data look rel compar
note orr overal respons rate six month slightli higher
vs yescarta albeit yescarta patient trial
note patient treat kymriah orr
patient month follow discontinu earlier evalu
efficaci think longer term real world data essenti determin
winner dlbcl car-t space also highlight abil administ
outpati set could alter usag curv one limit factor uptak
facil constrain notic higher proport patient treat
outpati set kymriah lesser extent patient
treat outpati set yescarta
think could edg safeti potenti neg
pressur yescarta usag note seem lower rate
cytokine-releas syndrom common side effect treatment patient
immun system goe drive releas larg amount cytokin
blood lower rate potenti indic safeti therapi less associ
risk death neurotox nt also key concern higher rate seen yescarta
kymriah patient highlight far fewer patient experienc nt
patient vs yescarta kymriah figur summar rel
efficaci safeti across three main target car-t therapi
charl martineau univers toronto figur car-t efficaci safeti comparison data
compani data nr report
month updat gener posit median durat
respons median overal surviv yet reach note see
stabil metric indic durabl respons believ
consist proport patient reach month surviv figur
detail updat
charl martineau univers toronto figur month dor os plot
treat salvag chemotherapi
expans earlier line dlbcl treatment could lead revenu upsid
enrol expect complet could set key data
earliest year believ
success asset predic move treatment paradigm safeti
eas administr remain core success earlier-lin treatment
car-t posit data set first relaps could paradigm shift view
current patient
follow
hematopoiet cell transplant aka bone marrow transplant patient inelig
bone marrow transplant limit option clear consensu treatment
current exist think patient first relaps set could elig
car-t head-to-head data car-t could prefer
autolog bone marrow transplant could diseas cell graft
administr effort includ administr pre-treat chemotherapi think
car-t therapi could done quicker limit hospit stay mskcc
suggest bone marrow transplant patient spend day hospit
hospit stay car-t week post administr yet see clinic
data includ sale model estim
move front line also highlight trial front-lin high-risk
dlbcl patient current patient high-risk diseas treat chemotherapi
rituximab think usag car-t could also viabl option especi
higher risk patient rituximab unlik produc deep durabl
result need see clinic trial design fulli understand clinic data
fulli comfort use earli continu believ chemotherapi plu
rituximab therapi remain standard care front line given clinic trial data support
regimen high year surviv rate consequenti
includ front-lin yescarta model revenu estim
expect data updat across platform upcom american societi clinic
oncolog may/jun notabl expect data trial look
yescarta first line treatment high-risk larg cell lymphoma data
present includ updat r/r acut lymphoblast leukemia
r/r chronic lymphocyt leukemia cll figur relev present
poster gilead
outcom larg b-cell lymphoma progress axicabtagen ciloleucel axi-cel result us
monitor ctdna r/r dlbcl patient follow t-cell therapi axicabtagen ciloleucel day
outcom patient pt year age pivot phase studi axicabtageneciloleucel
axi-cel refractori larg cell lymphoma lbcl
preliminari result earlier steroid use axicabtagen ciloleucel axi-cel patient
associ high baselin metabol tumor volum respons follow axicabtageneciloleucel
hematopoiet recoveri immun reconstitut axi-cel t-cell therapi patient
phase multicent studi axicabtagen ciloleucel axi-cel first-lin therapi patient
pt high-risk larg cell lymphoma lbcl
end phase result phase studi chimer antigen receptor
cell therapi adult patient pt relapsed/refractori r/r acut lymphoblast leukemia
phase multicent studi evalu patient pt relapsed/refractori r/r
kite platform could drive usag across hematolog malign howev
need see clinic data gain comfort ascrib valu
gilead emphas valu kite transact fulli evalu
peak sale potenti yescarta r/r dlbcl alon compani believ much
valu cell therapi platform expans yescarta beyond r/r dlbcl
disagre cell therapi platform import strateg move gilead
kite acquisit fail reacceler revenu earn growth key valuat metric
gilead peer inde ascrib much valu program target
without clinic data clear path forward concern compani wrote
anti-bcma asset acquir transact appreci
may competit car-t
forc us question dilig true understand platform show
stori enough re-rat gilead share view
asid dlbcl expect data trial mantl cell
lymphoma mcl mid-year set bla file fda
similar dlbcl mcl matur b-cell non-hodgkin lymphoma often
aggress vs indol nhl new name also
structur composit axicabtagen ciloleucel manufactur
slightli differ process gilead note manufactur slightli differ
process circul blast/tumor cell remov manufactur process
prior transduct see ruella et al link process mainli
use leukem malign accord armitag et al link mcl approxim
nhl us europ incid case per million per year
patient mcl abl surviv mani year without treatment uptod
guidelin suggest aggress treatment yield median os year
dlbcl rituximab plu chemotherapi mainstay use patient
candid bone marrow transplant mani patient regimen achiev
complet remiss mani patient eventu relaps inde current trial design
patient tri fail number combin therapi
includ chemotherapi rituximab approv r/r patient think could
increment opportun us peak like similar size
ou current model indic seen limit clinic
data patient still like take sever year sale reach
cll adult specif guidanc
trial read given initi expect
enrol could see data back half
earli updat data adult acut lymphoblast leukemia trial
present promis suggest high efficaci r/r patient
number evalu patient
undetect minim residu diseas mrd patient complet tumor remiss
longer term like get addit color broader kite platform
gilead overal oncolog strategi note compani work asset
target solid tumor addit allogen cartt
also known shelf car-t given earli natur asset
difficult valu program novel approach treat solid tumor
use tcr could valuabl need see clinic data develop
cell therapi hematolog malign difficult three key player
kite/gilead juno/celgen novarti move solid tumor also present
challeng figur gilead overal oncolog pipelin
think allogen approach could solv issu relat manufactur
howev yet see clinic data gilead program ind
asset expect compani nomin ahead gilead
name allogen found peopl kite allogen car-t novel
bispecif regeneron could competitor autolog car-t
therapi note field remain nascent clinic data need
approach determin better patient
w/ rituximab lenalidomid
allogen
activ enrol
activ enrol
prepar file ind
actual estim primari complet
finish enrol zuma
initi zuma combo w/ rituximab lenalidomid
finish enrol zuma
finish enrol zuma
file approv mcl zuma
file ind allogen
like new ceo strateg prioriti
less calendar quarter tenur much daniel oday strateg vision
gilead remain unknown whole like tone earn call
priorit follow
strengthen pipelin intern program busi
ensur optim commerci deliveri current market product
soon launch
ensur gilead right peopl right role well-
equip success
think oday open busi develop strengthen pipelin
reflect investor concern especi light failur
inde priorit find opportun supplement portfolio
partnership want balanc dividend polici need grow busi
long-term think decis action oper kite separ busi unit
ceo reflect time roch ceo pharmaceut
divis still await updat oday interact leadership team
board shape long-term strategi vision compani futur
roch manag pharmaceut divis oday oversaw smaller
dealspotenti indic approach toward busi develop get
better sens daniel oday may ceo review transact histori
roch ceo pharmaceut divis septemb
roch diagnost januari full roch biographi
found note roch largest acquisit recent memori genentech
tenur diagnost divis directli attribut oday
drive forc unlik oday drive forc behind roch recent
propos acquisit spark sec file indic formal discuss roch
repres ceo schwan spark repres ceo marrazzo start
decemb day follow announc oday appoint
overal oday ceo pharmaceut divis roch engag
approxim therapeut focus transact median deal size
largest intermun see figur roch unabl
success acquir roch diagnost european
colleagu indic help roch expand big data acquisit
foundat medicin announc june flatiron announc feb
us million
think oday unlik engag signific first year
inde track record roch suggest taken conserv
approach transact consist commentari call expect
much remaind focu develop long-term vision strategi
gilead think increment updat across pipelin includ result
plan meet fda determin path forward filgotinib ra help shape
vision compani
potenti cultur clash big pharma nimbl biotech
specif indic cultur clash oday gilead
current manag team note major pharma biotech differ
approach drug develop commerci european colleagu
cover roch number year indic compani tend take
conserv approach trial design duplic trial longer timelin get
sens high level urgenc within gilead produc success trial result
could help secur next leg growth compani think gilead lean
nimbl mindset could frustrat oday background big pharma oday
function experi oncolog rare diseas prior align
gilead expans cellular therapi note roch major
cellular therapi program oday departur thu direct
experi develop commerci car-t therapi
data could interest howev investor want pipelin success
commerci execut oday luxuri time resourc invest big data
platform roch includ flatiron health foundat medicin believ
big data like still role futur clinic trial gilead howev
think short term gilead investor need see posit pipelin develop
investor want see acceler expans car-t platform
anem full first year sale write key asset kite
sens oday manag roch pharmaceut roch
diagnost know translat run gilead oday
career man roch work firm year start variou us-
base commercial/sal role clearli know broader biopharma industri
lack perspect outsid roch background could present
challeng mix cultur could help reinvigor gilead powerhous
diversifi promis pipelin expect investor focu close oday
next year tri gaug alter strateg cours compani
draw board
failur
gilead foray nash non-alcohol steatohepat challeng
best recent late-stag failur brine question compani
develop plan diseas overal remain cautiou gilead develop
work nash support limit confid biolog selonsertib apoptosi
signal-regul kinas inhibitor phase monotherapi
trial selonsertib show evid activ vs placebo
trial lower dose selonsertib produc p-valu vs placebo see
figur detail higher mg dose slightli better placebo improv
fibrosi far statist signific
follow failur stellar program hope gilead intern
nash asset center data upcom atla trial trial includ
selonsertib focus combin data inhibitor fxr
agonist still enthusiasm gilead nash program low follow two
signific asset failur diseas selonsertib simtuzumab give gilead
credit nash asset dcf valuat compani
believ gilead would need acquir compani order leader
number patient
improv fibrosi without worsen week
phase data expect gilead fxr combin expect
part phase atla trial includ combin arm
selonsertibw believ arm show benefit interest
monotherapi combin arm inhibitor
acetyl-coa carboxylas agonist fxr farnesoid receptor
two drug act differ part nash patholog see figur
impact mechan ocaliva note atla program see figur
trial design highlight exploratorywith limit clinic data asset
charl martineau univers toronto figur nash target pathogen mechan
cilofexor/ frx agonist acquir shown mix efficaci
monotherapi agent data phase trial demonstr
improv hepat steatosi serum bile acid live biochemistri see figur
none accept endpoint fda approvalbut nonetheless demonstr
cilofexor like impact nash patient data smaller phase
trial support monotherapi efficaci see figur howev interpret
trial caution given size inclus selonsertib monotherapi
combin trial also show interest efficaci
improv liver fat measur mri-pdff magnet reson
image-proton densiti fat fraction data show proof concept
potenti relat fda-accept endpoint nash trialbut data remain
immatur far conclus
treatment
treatment
number patient
median rel chang baselin
mri-pdff
mri-pdff
median rel chang baselin
mre-stiff
median rel chang baselin
liver stiff fibroscan
median rel chang baselin
alt
median rel chang baselin
ggt
median rel chang baselin
fast
median rel chang baselin
median rel chang baselin
total bile acid
figur nash phase trial selonsertib cilofexor firsocostat
number patient
mri-pdff week
reduct mri-pdff week
mre week
alt week
ggt week
week
pii-np week
improv without worsen nash
despit signal earlier trial data atla trial requir
real confid gilead nash program need see data atla
trial examin patient includ primari endpoint assess
cilofexor/firsocostat combin arm posit trial gilead would like
need run larger phase trial approv data atla program alon
like enough regulatori review
intercept like player town follow posit top-lin data ocaliva
pivot regner trial trial demonstr statist signific
improv fibrosi score patient dose see figur nash
resolut hit saw trend high-dos patient expect
result suffici fda approv earli assum file mid-year
highlight intercept appear player nash sever
year could view attract target firm metabol space
number patient
worsen nash month
nash resolut ith worsen
liver fibrosi stage month
overal gilead lack success develop nash therapeut selonsertib
simtuzumab make difficult us full confid cilofexor
firsocostat think gilead prowess liver diseas name hcv primarili
deriv pharmasset acquisit knowledg infecti diseas vs expertis
nash continu find difficult reconcil phase trial poor result
question compani interpret biolog
nash base past studi use earlier phase data promot asset pivot
trial think gilead success nash compani may re-
think overal approach target select support better understand
biolog cilofexor firsocostat could success difficult us say given
seem posit signal phase trial selonsertib believ gilead
may need acquir becom market leader space doubt
compani could success commerci nash drug highlight must
viabl drug sell
hcv main driver revenu earn
upsid busi declin
hcv longer key driver earn upsid sale expect continu
declin peak ww sale sale
guidanc estim see figur hcv becom
believ steadi cash-flow unlik grow significantli inde
expect approxim patient initi therapi per quarter us per
year declin slightli time see figur
think current approach hcv make sens
gilead recent launch asegua therapeuticsoff author gener
epclusa harvoni reflect current net price therapeut us
market week cours therapi asegua therapeut sell vosevi
sofosbuvir/ velpatasvir/ voxilaprevir indic treatment experienc
patient fail inhibitor still see vosevi sale major
driver given use treatment-experienc patient
point hcv longer develop prioriti real budget
need cure nearli patient epclusa harvoni lesser
extent vosevi end gilead also invest signific amount sale
marketingand thu abl realiz much gross profit sale
asset estim small molecul drug
net-net gilead clear strategi hcvalign net cost gross cost open
access especi
commodit hcv cure reflect hcv sale estim show
slight declin go forward see figur next year hcv
could provid nearli free-cash flow aggreg assum gross margin
tax rate minim sg spend pale comparison sale
sovaldi-bas asset new realiti franchis area less
contentiousa rel line consensu believ near-term
perform franchis fairli reflect stock
medicaid segment still
approach point
charl martineau univers toronto figur hcv patient start gilead product thousand
forecast gilead incom statement balanc sheet statement
project fy revenu bottom-lin
forecast non-gaap ep figur incom
statement balanc sheet found figur statement cash flow
found figur
royalti contract revenu
filgotinib royalti glpg
total product sale
total product sale
total product sale
total product sale
profit loss tax
net loss attribut non-controlling interest
weight average share use calcul dilut ep
product sale
product sale
product sale
profit loss tax
gross margin product sale exclud filgotinib royalti
oper margin product sale
net margin product sale
cash equival
prepaid expens current asset
properti equip net
commit conting
accumul comprehens loss
figur gilead statement flow
statement flow
adjust reconcil net incom net cash
chang asset liabil
prepaid expens asset
accru liabil
net cash use oper activ
purchas market secur
net cash use invest activ
proce debt financ net
proce convert note hedg
purchas convert note hedg
proce issuanc common stock
repurchas common stock
repay debt oblig
payment settl warrant
excess tax benefit sbc
payment conting consider
payment dividend
net cash use financ activ
net decreas increas cash cash equival
cash equival begin period
cash equival end period
holt view gilead
run project holt valuat framework result
per share slightli target price
holt credit suiss proprietari methodolog compani analysi stock
select deliv object global consist view compani
holt use perform metric known return invest cfroi
adjust account distort compar econom perform across
sector region time appl appl basi holt valuat methodolog
base discount cash flow framework number distinguish featur
includ uniqu way calcul termin valu firm cost capit
base forecast holt dcf get warrant valuat per
share slightli target price due inclus long term liabil
holt debt deduct ev get equiti valu mainli compris
liabil repatri tax
beyond holt dcf framework appli mean revers methodolog
calcul termin valu assum cfroi discount rate fade gradual
long term averag asset growth fade reach averag growth
also run sensit analysi show valuat
sensit top line growth indic get target price holt impli
long term sale growth constant margin
charl martineau univers toronto figur holt analysi gilead
cs peer relationship gilead
peer global databas captur uniqu inform compani within
credit suiss coverag univers base relationship compani
custom supplier competitor databas built research analyst
insight regard relationship credit suiss cover compani global
compani form core peer databas also includ relationship
stock coverag figur
figur cs peer relationship map gilead
author report evan seigerman would like acknowledg work
matthew terwelp md adrian garcia associ credit suiss larg cap
daniel oday chairman chief execut offic
mr oday join gilead prior gilead serv chief execut offic
career roch span three decad
held number execut posit compani pharmaceut
diagnost divis north america europ asia time roch help
engin acquisit flatiron health foundat medicin hold
bachelor degre biolog georgetown univers columbia
univers new york
robin washington execut vice presid chief offic
ms washington join gilead senior vice presid chief
offic overse global financ inform technolog organ
promot execut vice presid prior previous
chief offic hyperion solut prior senior vice presid
corpor control peoplesoft current member board
director honeywel intern board director
board visitor graziadio school busi manag pepperdin univers
certifi public account hold bachelor degre busi
administr univers michigan pepperdin univers
john mchutchison chief scientif offic head research develop
dr mchutchison join gilead appoint chief scientif offic
march prior join gilead work duke univers medic center
serv associ director duke clinic research institut also held
posit professor medicin divis gastroenterolog duke univers
medic center associ director duke clinic research institut co-director
duke clinic translat scienc award prior posit duke spent
nearli year scripp clinic recent medic director liver transplant
also previous held assist professorship medicin univers
southern california undergradu degre medicin surgeri
univers melbourn australia complet resid intern medicin
fellowship gastroenterolog royal melbourn hospit member
royal australasian colleg physician
andrew dickinson execut vice presid corpor develop strategi
mr dickinson join gilead respons overse compani
corpor develop allianc manag competit intellig corpor
strategi plan group help engin compani acquisit kite
pharma inc prior join gilead serv global co-head healthcar
invest bank lazard lazard advis numer merger
acquisit transact mr dickinson receiv bachelor degre molecular
cellular development biolog univers colorado law degre
loyola univers chicago
dr join director pharmaceut product develop
appoint execut vice presid research respons
expans compani research preclin activ across rang
therapeut area includ hiv liver diseas hematolog oncolog inflamm
respiratori diseas cardiovascular condit prior join gilead
head drug deliveri california biotechnolog inc began career research
scientist syntex research palo alto california receiv bs chemistri
univers massachusett phd chemistri univers california san
diego perform postdoctor work ecol polytech feder lausann
univers california santa barbara
brett pletcher execut vice presid chief complianc offic
brett pletcher join current execut vice presid
gener counsel chief complianc offic overse legal organ
complianc effort associ promot gilead product interact
healthcar profession payer also serv corpor secretari prior
join gilead partner law firm gunderson dettmer llp receiv
bachelor degre econom polit scienc univers california
riversid law degre univers california berkeley boalt
school law member california state bar former member
nasdaq list hear review council serv advisori board
mr alton lead gilead patient outreach engag initi compani
effort facilit access medicin around world overse corpor
medic affair function develop world access program well digit
patient solut patient-cent outcom group commerci oper
certain countri sinc join gilead held number posit
compani experi legal medic affair polici commerci previous
serv gener counsel prior gilead attorney law firm cooley
godward llp receiv bachelor degre legal studi univers
california berkeley law degre stanford univers
ms hamil join gilead respons lead compani commerci
oper prior gilead held number intern execut
posit serv recent senior vice presid commerci
oper also held varieti role biopharmaceut industri
includ posit hoffmann-la roch klemtner advertis current serv
advisori board women busi leader industri
foundat receiv bachelor degre busi administr
univers arizona
taiyin yang execut vice presid pharmaceut develop
dr yang join gilead appoint current role execut vice
presid pharmaceut develop manufactur januari
respons chemistri manufactur control oper small molecul
gilead
investig commerci product prior join gilead director
analyt chemistri syntex receiv bachelor degre chemistri
nation taiwan univers phd organ chemistri univers
inform qualiti assur
ms watson lead compani world-wide human resourc organ join
gilead februari prior current role held number posit
hr organ join gilead ms watson work applera corp appli
biosystem led hr consult practic trinet serv hr busi
partner shaw co hold degre psycholog univers
california san diego master organiz psycholog columbia
figur phase filgotinib efficaci compar data
cdmard-ir patient potenti favor filgotinib olumi xeljanz
ef ic su
filg ib
 ib
figur phase filgotinib efficaci compar compar
effic su
figur phase finch filgotinib efficaci compar compar
ef ic su
filg ib
 ib
nash primer overview
nonalcohol steatohepat nash inflammatory-deriv symptomat stage
nonalcohol fatti liver diseas nafld nafld aris excess fat store
liver vesicl within hepatocyt condit call steatosi nafld co-morbid
metabol syndrom syndrom also includ obes diabet
hyperlipidemia name suggest heavi alcohol use must factor diagnos
nafld nafld without inflamm benign condit believ
nash market continu grow see figur
nash aris nafld lead inflamm liver hepat lead liver cell
damag combin inflamm liver cell damag result fibrosi
scar liver chronic build-up fibrosi liver nash lead
cirrhosi and/or liver cancer hepatocellular carcinoma eventu progress
liver failur decompens ultim death
like pbc nash typic silent diseas symptom year
mani patient remain asymptomat approach later stage even
cirrhosi metabol signal may indic presenc nash includ overweight
obes hypercholesterolemia hypertriglyceridemia type diabet and/or sign
metabol syndrom includ larg waist size high triglycerid low hdl elev
glucos high blood pressur
unlik pbc nash rare diseas estim peopl nafld
unit state alon estim nash
on-going global obes epidem number expect grow approxim
est et al hepatolog accord nation institut diabet
digest kidney diseas niddk roughli us adult nafld
nash though nafld like develop age fatti
liver occur age children age estim nafld
nash progress liver diseas increas fibrosi level lead sever risk
liver failur hepat cellular carcinoma cardiovascular event heart attack
stroke etc nash expect surpass hepat alcohol lead
caus liver transplant us within next decad estim
suggest earli canbay et al viscer medicin
current therapi approv nash fda current standard care
diet exercis effect patient treatment commonli
use nash patient even though fda approv one vitamin
supplement pioglitazon agonist peroxisom proliferator-
activ receptor ppar niddk perform studi piven evalu
treatment adult nash patient treatment posit effect
neither abl improv underli condit patient qualiti life
charl martineau univers toronto figur credit suiss nash patient estim fibrosi stage
estim diagnos us nash patient
fda guidanc nash therapi
fda recent publish draft guidanc develop therapi treat
noncirrhot nonalcohol steatohepat liver fibrosi indic
two separ distinct pathway approv treat nash patient
nash resolut without worsen fibrosi recent publish
draft guidanc industri fda defin resolut steatohepat
overal histopatholog read worsen liver fibrosi nash crn
fibrosi score resolut steatohepat defin absent fatti liver diseas
isol simpl steatosi without steatohepat nafld activ score
na inflamm balloon valu steatosi
defin
improv liver fibrosi greater equal one stage nash crn fibrosi
score worsen steatohepat defin increas na
balloon inflamm steatosi
worsen nash
primari caveat two independ complimentari approv endpoint
must demonstr histolog word requir liver biopsi
potenti pain invas procedur begin studi baselin
studi endpoint typic year initi studi requir biopsi
approv one potenti point concern nash market whether payor
also requir biopsi proof diagnosi nash gateway reimburs
current four compet drug phase trial intercept ocaliva gilead
selonsertib genfit elafibranor allergan cenicriviroc addit
drug stage least phase ii develop later vari mechan
compani mention price
